FindTrial
Sign In

Prevalence of High-Risk Human Papilloma Virus in HIV Positive women

Prevalence of High-Risk Human Papilloma Virus with Genotype Assessment in HIV Positive women: A Cross sectional study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/052348
Enrollment
160
Registered
2023-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: Screening for cervical cancer using HPV test and treatment: HIV positive women will be screened for HPV DNA using PCR based test (validated by Cobas test) and HPV positive cases will un

Sponsors

Molbio Diagnostics Private limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All women > 25 years of age attending ART clinic of AIIMS Rishikesh with HIV seropositive status

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Women who have undergone conization or hysterectomy 3. Not willing to participate in study

Design outcomes

Primary

MeasureTime frame
To quantify the number of women with high-risk HPV positivity in HIV seropositive women To study the distribution of various high risk HPV genotypes in HIV positive womenTimepoint: Once (at recruitment)—

Secondary

MeasureTime frame
Duration of HIV seropositivity (in months since diagnosis) in high-risk HPV positive women. Duration of ART in weeks in the above group. CD4 cell count (cells/mm3) at recruitment. Number of women with cytological abnormalities â?¥ ASCUS. Number of cases with CIN and invasive cervical cancer Timepoint: Once (at recruitment)—

Countries

India

Contacts

Public ContactDr Shalini Rajaram

AIIMS Rishikesh

rajaram.shalini@gmail.com9810704434

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026